Skip to content

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus Infection in Soldiers: a Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00289588
Enrollment
3000
Registered
2006-02-10
Start date
2005-01-31
Completion date
2005-12-31
Last updated
2006-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-Acquired MRSA Infections, Abscesses, Cellulitis, Folliculitis

Keywords

Methicillin-resistant Staphylococcus aureus, Staphylococcus aureus, MRSA, CA-MRSA

Brief summary

The main purpose of this study is to determine if applying mupirocin into soldiers noses who are colonized with methicillin-resistant Staphylococcus aureus (MRSA) will reduce infections in them and their cohort of fellow soldiers.

Detailed description

Community-acquired MRSA infections are increasingly common in the community and in particular among certain groups of which soldiers are one. Many researchers and clinicians have postulated that one method to prevent infections is to selectively eradicate CA-MRSA in those who are colonized with the pathogen. The two main purposes of the study are: to determine if selective CA-MRSA eradication in subjects reduces infections in the CA-MRSA colonized individual; and to determine if selective CA-MRSA eradication in subjects reduces infections in the study cohort. Other information concerning CA-MRSA includes: prevalence, risk factors, and virulence data. The population will be soldiers enrolled in the combat medic training class at Ft. Sam Houston. We will enroll approximately 3000 soldiers over a two year period. After informed written consent, we will culture their anterior nares nares and administer questionnaires at the beginning and at the end of the study, following them prospectively for infections. The follow-up period will be 16 weeks. For those with CA-MRSA in their nares, they will be randomized (by cohort) to receive either 5 days of mupirocin or placebo.

Interventions

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
Becton, Dickinson and Company
CollaboratorINDUSTRY
Brooke Army Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
17 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

Soldiers enrolled into the combat medic course at Ft. Sam Houston, TX. \-

Exclusion criteria

Allergy to mupirocin. \-

Design outcomes

Primary

MeasureTime frame
Soft tissue infections in subjects who received the study medication and soft tissue infections in the study cohorts.

Secondary

MeasureTime frame
Changes in S. aureus carriage rates (including MRSA).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026